A Study to Test CRT-402 in Refractory Autoimmune Disease

StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Patients with refractory autoimmune diseases often have limited treatment options and ongoing disease activity despite standard therapies. CRT-402 is an in vivo Cluster of differentiation 19 (CD19)-targeted CAR-T cell therapy designed to deplete CD19-positive B cells and promote immune system reset. This study evaluates the safety, tolerability, preliminary efficacy, pharmacodynamics (PD), and pharmacokinetics (PK) of CRT-402 in participants with active refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM).
Trial Details
NCT Number NCT07778446
Lead Sponsor Myeloid Therapeutics
Collaborators: CREATE Medicines
Conditions
(from sponsor)		 Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma, Myositis
Related terms Autoimmune Diseases, Lupus Erythematosus, Systemic, Myositis, Scleroderma, Systemic
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov